GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » G.Barekat Pharm (XTEH:BRKT1) » Definitions » Sale Of Investment

G.Barekat Pharm (XTEH:BRKT1) Sale Of Investment : IRR Mil (TTM As of Mar. 2017)


View and export this data going back to 2017. Start your Free Trial

What is G.Barekat Pharm Sale Of Investment?

G.Barekat Pharm's sale of investment for the six months ended in Mar. 2017 was IRR0 Mil. It means G.Barekat Pharm gained IRR0 Mil from selling investments.

Compared with last quarter (IRR0 Mil in Mar. 2016 ), G.Barekat Pharm gained the same money from selling investments in Mar. 2017 (IRR0 Mil).


G.Barekat Pharm Sale Of Investment Historical Data

The historical data trend for G.Barekat Pharm's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

G.Barekat Pharm Sale Of Investment Chart

G.Barekat Pharm Annual Data
Trend Mar16 Mar17
Sale Of Investment
- -

G.Barekat Pharm Semi-Annual Data
Mar16 Mar17
Sale Of Investment - -

G.Barekat Pharm Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.


G.Barekat Pharm Sale Of Investment Related Terms

Thank you for viewing the detailed overview of G.Barekat Pharm's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


G.Barekat Pharm (XTEH:BRKT1) Business Description

Traded in Other Exchanges
N/A
Address
No. 11, 5th Alley, Bucharest Avenue, Argentina Square, Tehran, IRN
G.Barekat Pharm focuses on the introduction of new pharmaceutical fields such as biotechnology, drug delivery which includes nanotechnology, slow release drugs, and new technologies for health, development of cellular molecular industries like tuberculosis, gene therapy, immunotherapy, and tissue technology.

G.Barekat Pharm (XTEH:BRKT1) Headlines

No Headlines